Why the study?
Does bovine internal mammary artery graft provide acceptable long-term patency compared to native grafts in patients undergoing coronary revascularization?
Does bovine internal mammary artery graft provide acceptable long-term patency compared to native grafts in patients undergoing coronary revascularization?
Bovine internal mammary artery grafts demonstrate unacceptably low long-term patency rates compared to autologous grafts for coronary revascularization.
Answers are grounded in this paper and cite their sources.
Avoid bovine IMA grafts in CABG; this case report challenges their role and leaves open conduit selection questions.
Graft patency after coronary artery bypass grafting depends largely on the choice of conduit. Because an increasing number of patients have insufficient or poor-quality autologous material, there is a need for a suitable synthetic graft that is readily available and easy to handle and that has good long-term patency. Early results suggest that the bovine internal mammary artery graft may meet these criteria. We have used a total of 26 such grafts in 18 patients. Postoperative angiography has been performed in 19 grafts in 14 patients, 3 to 23 months after operation; of these grafts, 3 are currently patent (15.8%, compared with 85.7% and 75.0% patency for native internal mammary artery and saphenous vein grafts in the same patients). We report the results of clotting studies and an analysis of lipid status. These patients do not, however, appear to represent any atypical group, either in terms of coagulopathy, native coronary artery size, or the type of vessel disease. Nevertheless, our poor results contrast markedly with the early enthusiasm reported from other centers.
No takes yet. Share an insight, caveat, or question.
Mitchell et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: